Pfizer Inc. crushed Q2 estimates with a 36% EPS beat, proving its operational turnaround is gaining momentum. Click here to find out why PFE stock is a Buy.
Why The Market Is Dangerously Wrong About Pfizer Stock (NYSE:PFE)
Seeking Alpha Stock5 hrs ago
79
America News
Essentiallysports Golf
Cover Media
Essentiallysports Basketball
AlterNet
FOX Business Video
Newsweek Top
New York Post Video
The Conversation